Validating therapeutic targets through human genetics
- 19 July 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 12 (8), 581-594
- https://doi.org/10.1038/nrd4051
Abstract
More than 90% of the compounds that enter clinical trials fail to demonstrate sufficient safety and efficacy to gain regulatory approval. Most of this failure is due to the limited predictive value of preclinical models of disease, and our continued ignorance regarding the consequences of perturbing specific targets over long periods of time in humans. 'Experiments of nature' - naturally occurring mutations in humans that affect the activity of a particular protein target or targets - can be used to estimate the probable efficacy and toxicity of a drug targeting such proteins, as well as to establish causal rather than reactive relationships between targets and outcomes. Here, we describe the concept of dose-response curves derived from experiments of nature, with an emphasis on human genetics as a valuable tool to prioritize molecular targets in drug development. We discuss empirical examples of drug-gene pairs that support the role of human genetics in testing therapeutic hypotheses at the stage of target validation, provide objective criteria to prioritize genetic findings for future drug discovery efforts and highlight the limitations of a target validation approach that is anchored in human genetics.Keywords
This publication has 113 references indexed in Scilit:
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseNature, 2012
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Genetics of gene expression in primary immune cells identifies cell type–specific master regulators and roles of HLA allelesNature Genetics, 2012
- The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysisThe Lancet, 2012
- Five Years of GWAS DiscoveryAmerican Journal of Human Genetics, 2012
- Integrating Autoimmune Risk Loci with Gene-Expression Data Identifies Specific Pathogenic Immune Cell SubsetsAmerican Journal of Human Genetics, 2011
- Variation in complement factor 3 is associated with risk of age-related macular degenerationNature Genetics, 2007
- A haplotype map of the human genomeNature, 2005
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- Genetic dissection of complex traits: guidelines for interpreting and reporting linkage resultsNature Genetics, 1995